Drug Trial Radar · NCT04085172
A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
396
Actual
Start
Sep 18, 2019
Primary completion
Sep 2, 2025
Study completion Sep 2, 2025
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Takeda Development Center Americas, Inc.
- First posted
- Sep 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B). In Part A, participants will take tablets of TAK-503, atomoxetine or placebo and in Part B TAK-503 tablets.
Conditions
- Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine hydrochloride (TAK-503)Drug
Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablets once daily for 18 weeks in Part A or 52 weeks in Part B.
Atomoxetine hydrochlorideDrug
Participants will receive Atomoxetine hydrochloride oral capsule once daily for 18 weeks in Part A.
PlaceboOther
Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg placebo matched to TAK 503 oral tablets once daily for 18 weeks and placebo matched to atomoxetine hydrochloride oral capsules at once daily for 18 weeks in Part A.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Change From Baseline in the Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI) Task at Week 18Time frame: At Baseline, Week 18
- Part A: Change From Baseline in the CANTAB RTI Task at Week 49Time frame: At Baseline, Week 49
- Part B: Change From Baseline in the CANTAB RTI Task at Week 49Time frame: At Baseline, Week 49
Locations
50 sites in 9 countries. Site status is shown where the registry gives one.
Harmonex Neuroscience Research
Dothan, Alabama
Advanced Research Center, Inc.
Anaheim, California
Sun Valley Research Center, Inc.
Imperial, California
Alliance Research
Long Beach, California
PCSD Feighner Research
San Diego, California
Homestead Medical Research
Homestead, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Care Research Center, Inc.
Miami, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
AMR Conventions Research, Ltd
Naperville, Illinois
Collective Medical Research LLC
Prairie Village, Kansas
Qualmedica Research, LLC
Bowling Green, Kentucky
Qualmedica Research, LLC
Owensboro, Kentucky
Alivation Research, LLC
Lincoln, Nebraska
Center for Psychiatry and Behavioral Medicine, Inc.
Las Vegas, Nevada
University of Cincinnati
Cincinnati, Ohio
Cutting Edge Research Group
Oklahoma City, Oklahoma
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee
Family Psychiatry of The Woodlands
The Woodlands, Texas
Clinical Research Partners, LLC
Petersburg, Virginia
LKH-Klinikum Graz
Graz, Austria
Medizinische Universtität Wien
Vienna, Austria
UZ Brussel
Brussels, Belgium
UPC KU Leuven Afdeling Kinderpsychiatrie ADHD-raadpleging
Leuven, Belgium
Foyer Saint Francois
Namur, Belgium
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Germany
Zentralinstitut fuer Seelische Gesundheit
Mannheim, Baden-Wurttemberg, Germany
Universitaetsklinikum Koeln
Cologne, North Rhine-Westphalia, Germany
Rheinhessen-Fachklinik Mainz
Mainz, Rhineland-Palatinate, Germany
EB FlevoResearch
Almere Stad, Netherlands
EB UtrechtResearch
Utrecht, Netherlands
Hospital de Cascais - Dr. José de Almeida
Alcabideche, Portugal
Centro Clinico Academico 2CA Associacao Braga, Hospital de Braga Piso 1, Ala E
Braga, Portugal
Centro Hospitalar Universitario Cova da Beira, E.P.E
Covilha, Portugal
Hospital da Senhora da Oliveira Guimarães
Guimarães, Portugal
Hospital CUF Descobertas
Lisbon, Portugal
Centro Materno Infantil do Norte (CMIN) Centro Hospitalar Universitario do Porto
Porto, Portugal
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Clinica Dr. Quintero
Madrid, Spain
Hospital Infanta Leonor
Madrid, Spain
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.